2GH Stock Overview A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Merus Historical stock prices Current Share Price US$39.60 52 Week High US$55.50 52 Week Low US$24.60 Beta 1.09 1 Month Change -2.94% 3 Month Change -6.60% 1 Year Change 67.80% 3 Year Change 41.43% 5 Year Change 193.33% Change since IPO 179.38%
Recent News & Updates
Merus N.V. Announces That the United States Food and Drug Administration Approves Bizengri (Zizengri) for Treatment Indicated for Adults with Pancreatic Adenocarcinoma or Non Small Cell Lung Cancer Dec 05
Third quarter 2024 earnings released: US$1.46 loss per share (vs US$0.43 loss in 3Q 2023) Nov 01
Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC Oct 01
Second quarter 2024 earnings released: US$0.81 loss per share (vs US$0.66 loss in 2Q 2023) Aug 04
Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC Jul 08
Merus N.V. Announces Chief Medical Officer Changes Jul 02 See more updates
Merus N.V. Announces That the United States Food and Drug Administration Approves Bizengri (Zizengri) for Treatment Indicated for Adults with Pancreatic Adenocarcinoma or Non Small Cell Lung Cancer Dec 05
Third quarter 2024 earnings released: US$1.46 loss per share (vs US$0.43 loss in 3Q 2023) Nov 01
Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC Oct 01
Second quarter 2024 earnings released: US$0.81 loss per share (vs US$0.66 loss in 2Q 2023) Aug 04
Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC Jul 08
Merus N.V. Announces Chief Medical Officer Changes Jul 02
Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting Jun 05 Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million. May 31
Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million. May 29
Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA May 15
First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023) May 09
Merus N.V. Appoints Jason Haddock as Non-Executive Director May 09
Merus N.V., Annual General Meeting, May 07, 2024 Apr 11 Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc. Mar 07
Full year 2023 earnings released: US$3.00 loss per share (vs US$2.92 loss in FY 2022) Mar 01 Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million. Feb 29
Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.53 loss in 3Q 2022) Nov 04
Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer Oct 24
Second quarter 2023 earnings released: US$0.66 loss per share (vs US$0.13 loss in 2Q 2022) Aug 08
U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V Jul 06
Merus Appoints Greg Perry as Chief Financial Officer Jun 16
First quarter 2023 earnings released: US$0.86 loss per share (vs US$0.43 loss in 1Q 2022) May 07
Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021) Mar 02
Merus N.V. Announces Executive Changes Jan 07 Dec 12
Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.39 loss in 3Q 2021) Nov 05
Merus N.V. Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics Oct 27
Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.71 loss in 2Q 2021) Aug 10
Merus N.V. Presents Clinical Data on Zenocutuzumab in NRG1-Fusion Cancer at the 2022 American Society of Clinical Oncology Annual Meeting Jun 06
First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.28 loss in 1Q 2021) May 11
Merus N.V., Annual General Meeting, May 31, 2022 May 02 Merus N.V. Announces Publication of Abstract on MCLA-129 At the American Association for Cancer Research 2022 Annual Meeting Mar 10
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 04
Merus N.V. Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at San Antonio Breast Cancer Symposium Dec 11
Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.79 loss in 3Q 2020) Nov 04
Second quarter 2021 earnings released: US$0.71 loss per share (vs US$0.62 loss in 2Q 2020) Aug 09
Forecast to breakeven in 2024 Jun 23
Forecast to breakeven in 2024 Jun 08
Forecast to breakeven in 2024 Jun 06
Merus N.V. Presents Clinical Data on Zenocutuzumab in Nrg1-Fusion (Nrg1+) Cancers At the American Society of Clinical Oncology (Asco) 2021 Annual Meeting Jun 05
Forecast to breakeven in 2024 Jun 03
Forecast to breakeven in 2024 Jun 01
Forecast to breakeven in 2024 May 29
Forecast to breakeven in 2024 May 26
Forecast to breakeven in 2024 May 23
Merus N.V. Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting May 21
Forecast to breakeven in 2024 May 20
Forecast to breakeven in 2024 May 18
Forecast to breakeven in 2024 May 17
Forecast to breakeven in 2024 May 14
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial May 14
First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.57 loss in 1Q 2020) May 08
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors May 04
Full year 2020 earnings released: US$2.92 loss per share (vs US$2.28 loss in FY 2019) Mar 18
Loxo Oncology at Lilly and Merus N.V. Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies Jan 22
Merus N.V. Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial Jan 13
Merus N.V. Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium Jan 12
New 90-day high: €16.00 Jan 12
U.S. Food and Drug Administration Grants Merus N.V. Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers Jan 08
New 90-day high: €14.70 Dec 10
New 90-day high: €11.40 Nov 13
New 90-day low - €10.50 Aug 22
New 90-day low - €11.10 Aug 06 Shareholder Returns 2GH DE Biotechs DE Market 7D -1.0% -2.6% -2.0% 1Y 67.8% -13.2% 6.8%
See full shareholder returns
Return vs Market: 2GH exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 2GH's price volatile compared to industry and market? 2GH volatility 2GH Average Weekly Movement 8.5% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2GH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2GH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
Show more Merus N.V. Fundamentals Summary How do Merus's earnings and revenue compare to its market cap? 2GH fundamental statistics Market cap €2.75b Earnings (TTM ) -€234.99m Revenue (TTM ) €34.53m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2GH income statement (TTM ) Revenue US$35.93m Cost of Revenue US$146.08m Gross Profit -US$110.15m Other Expenses US$134.41m Earnings -US$244.56m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.57 Gross Margin -306.55% Net Profit Margin -680.61% Debt/Equity Ratio 0%
How did 2GH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 17:13 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Merus N.V. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Etzer Darout BMO Capital Markets Equity Research Evan Seigerman BMO Capital Markets Equity Research Tazeen Ahmad BofA Global Research
Show 19 more analysts 
